Scottish Brain Sciences (SBS), a leading clinical research organization dedicated to transforming the early detection and treatment of Alzheimer’s disease and other neurodegenerative conditions, today announced that it has opened a new state-of-the-art clinical research center at ONE BioHub, Aberdeen. The new clinical research center will enable people living with Alzheimer’s disease, and those concerned with memory issues, to participate in studies focused on the early detection and treatment of Alzheimer’s and other neurodegenerative conditions.
The clinical research center at ONE BioHub becomes SBS’s third research facility, complementing the Company’s research hub in St Andrews and its Edinburgh headquarters. The new facility will allow SBS to conduct clinical studies focused on early diagnosis, intervention, and precision trials to advance the global understanding and treatment of Alzheimer’s and related disorders.
By establishing a presence within ONE BioHub, a launchpad for start-ups and high potential life science companies looking to rapidly scale and grow, SBS joins a growing network of research-driven companies including NovaBiotics and Genomes.io already based at ONE BioHub. From ONE BioHub, SBS will play a central role in connecting brain health research with clinical and commercial pathways, strengthening Scotland’s position as an international hub for brain health innovation and further contributing to the country’s wider life sciences growth strategy.
The Aberdeen site was officially opened on 14th November by Aberdeen-based research participant, Lynne Carroll and was also attended by Richard Lochhead MSP, Minister for Business and Employment, who will highlight the Company’s investment as a boost to Scotland’s innovation economy and public health landscape.
The people of the north-east deserve early access to breakthroughs in brain health and dementia research. This new site will help ensure that people here can take part in trials, receive advanced assessments, and contribute to discoveries that could change the future of Alzheimer’s disease. Inviting one of our research participants to officially open this center reflects our belief that progress begins and ends with the people who volunteer to take part. They are the beating heart of discovery.”
Professor Craig Ritchie, CEO and Founder, Scottish Brain Sciences
Lynne Carroll, Scottish Brain Sciences research participant, added: “It took several years to receive my Alzheimer’s diagnosis, and that is the reality for so many people. By being part of research that aims to detect and treat Alzheimer’s earlier, I hope I can help make the path a little clearer for others in the future. I reached out to Scottish Brain Sciences some time ago as I was eager to contribute. When they shared plans to open a research site in Aberdeen, I was thrilled, as it means I will be able to take part in trials that may require regular visits. It is a privilege to be involved in today’s opening, and I would encourage anyone locally affected by Alzheimer’s to connect with the team.”
Dr Deborah O’Neil OBE FRSE, Chair, ONE Life Sciences and BioAberdeen Ltd: “We are delighted that Scottish Brain Science is expanding at ONE BioHub. Their focus on advancing understanding and treatment of neurological conditions adds important strengths to our growing life sciences cluster. The north east has a vibrant community of life science innovators and it is wonderful to see our first tenant growing and scaling within ONE BioHub.”
